Zobrazeno 1 - 10
of 47
pro vyhledávání: ''
Publikováno v:
Tumori Journal. 108:258-262
Introduction: Lung cancer is the most common cause of cancer-related death in the world. Changes in the treatment of metastatic lung cancer in recent years have made targetable mutations gain importance. MET alteration is one of these driver mutation
Publikováno v:
Tumori Journal. 107:119-124
Objective: To determine the combined efficacy of piperlongumine and gemcitabine for treatment of KRAS mutant lung cancer. Methods: The cell growth inhibition of piperlongumine, gemcitabine, and piperlongumine plus gemcitabine was measured by Cell Cou
Publikováno v:
Tumori Journal. 106:NP79-NP83
Background: Papillary renal cell carcinoma (pRCC) represents the second most common histologic subtype of renal cell carcinoma and comprises 2 subtypes. Prognosis for type 2 is associated with poor clinical outcome. Current guidelines are based on ph
Autor:
Claudio Zamagni, A. Marino, Gianfranco Filippelli, Claudio Scavelli, Caterina Fontanella, Antonio Febbraro, Anna Maria Quaranta, Pasqualinda Ferrara, Paola Schiavone, Laura Orlando, Palma Fedele, Eufemia Stefania Lutrino, Guido Giordano, Gianluca Dima, Chiara Caliolo, Nicola Calvani, Saverio Cinieri, Mariangela Giampaglia, Daniela Rubino, Domenico Bilancia
Publikováno v:
Tumori
Background: Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer (BC). Limited data regarding the safety and activity of the combination of eribulin and tra
New Drugs in the Treatment of Elderly Patients with Metastatic Castration-Resistance Prostate Cancer
Publikováno v:
Tumori Journal. 102:361-366
Treatment of prostate cancer is continually evolving and new therapies have become available. However, the management of elderly patients is challenging due to their age and comorbidities. Androgen deprivation therapy remains the mainstay treatment o
Publikováno v:
Tumori Journal. 96:764-767
The treatment of pancreatic cancer remains a formidable challenge to clinicians. Here we describe the case of a 57-year-old man with metastatic pancreatic cancer who received combination treatment with cetuximab and capecitabine plus gemcitabine for
Autor:
Massimiliano Villani, Alessandra Busia, Chiara Vismara, Simonetta Viviani, Fabrizio Villani, Valeria Bonfante
Publikováno v:
Scopus-Elsevier
Aims and Background Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkin's disease, can produce lung toxicity leading to fibrosis. There is increasing evidence of the involvement in the fib
Publikováno v:
Tumori Journal. 93:129-132
Aims and Background The purpose of the present retrospective study was to evaluate efficacy and safety of a lower dose-intensity capecitabine monotherapy regimen in heavily pretreated patients with metastatic breast cancer. Methods Patients with meta
Autor:
Vasilis Kouloulias, Dionysios Voros, Despina Mouratidou, Constantine Gennatas, Nikolaos Tsavaris, Nikiforita Poulakaki, J. Psychogios, Vasiliki Michalaki, George Katsiamis, Eleni Carvounis
Publikováno v:
Scopus-Elsevier
Aims and Background The understanding of hormonal therapies in postmenopausal women with metastatic breast cancer has advanced greatly in the past several decades. With the introduction of orally active, potent and selective third-generation aromatas
Autor:
Nobuyuki Mizunuma, Akimasa Nakao, Goi Sakamoto, Keiichiro Tada, Futoshi Akiyama, Daigo Hashimoto, Masataka Sawaki, Shunji Takahashi, Tsuneo Imai, Noboru Horikoshi, Fujio Kasumi, Yoshinori Ito, Kiyohiko Hatake
Publikováno v:
Scopus-Elsevier
Aims and background We evaluated retrospectively the efficacy and toxicity of paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Study design Paclitaxel (80 mg/m2) was administered weekly to 44 patients who had previously recei